Short-term complications of intravitreal injection of triamcinolone acetonide

• Published in: Retina (Philadelphia, Pa.) Vol. 28; no. 1; p. 66
• Main Authors: Roth, Daniel B, Realini, Tony, Feuer, William J, Radhakrishnan, Ravi, Gloth, Jonathan, Heimmel, Mark R, Fechtner, Robert D, Yarian, David L, Green, Stuart N
• Format: Journal Article
• Language: English
• Published: United States 01.01.2008
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Child; Choroid Diseases - drug therapy; Female; Glucocorticoids - adverse effects; Humans; Injections; Intraocular Pressure - drug effects; Male; Middle Aged; Ocular Hypertension - chemically induced; Retinal Diseases - drug therapy; Retrospective Studies; Triamcinolone Acetonide - adverse effects; Vitreous Body
• ISSN: 0275-004X
• DOI: 10.1097/IAE.0b013e3181593e38

To describe the short-term complications associated with intravitreal triamcinolone acetonide (IVTA) injection in the treatment of posterior segment disorders. The medical records of 784 patients (929 consecutive eyes) were retrospectively reviewed at a single institution. One or more IVTA injections for treatment of a variety of steroid-responsive posterior segment disorders (predominantly diabetic macular edema, choroidal neovascularization, and retinal venous occlusions) were administered. Adverse events occurring within 3 months of the initial injection were identified. The most common adverse event occurring within 3 months after the initial injection was steroid-related ocular hypertension, with intraocular pressure spikes of >21 mm Hg in 21% of eyes and >25 mm Hg in 11% of eyes. Ocular inflammation occurred in six eyes (0.6%): four eyes with sterile hypopyon and two eyes without hypopyon. Three eyes (0.3%) had corneal epithelial defects thought to be related to pretreatment with povidone-iodine solution. No eyes had culture-positive infectious endophthalmitis. Cataract progression was not assessed in this analysis. IVTA injection for the treatment of steroid-responsive disorders of the posterior segment, when administered under sterile conditions, is associated with a low incidence of serious vision-threatening adverse events within the first 3 months after injection.